{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:07:29Z","timestamp":1771661249098,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/nrneurol.2016.86","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T10:28:38Z","timestamp":1466159318000},"page":"373-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["No more mistaken identities for botulinum neurotoxins"],"prefix":"10.1038","volume":"12","author":[{"given":"Alberto","family":"Albanese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,17]]},"reference":[{"key":"BFnrneurol201686_CR1","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson, D. M.  et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache : report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 86, 1818\u20131826 (2016).","journal-title":"Neurology"},{"key":"BFnrneurol201686_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1212\/01.wnl.0000311391.00944.c4","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson, D. M.  et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1691\u20131698 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol201686_CR3","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson, D. M.  et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1699\u20131706 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol201686_CR4","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1212\/01.wnl.0000311390.87642.d8","volume":"70","author":"M Naumann","year":"2008","unstructured":"Naumann, M.  et al. Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70, 1707\u20131714 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol201686_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jama.2010.1937","volume":"305","author":"A Albanese","year":"2011","unstructured":"Albanese, A. Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA 305, 89\u201390 (2011).","journal-title":"JAMA"},{"key":"BFnrneurol201686_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","volume":"18","author":"A Albanese","year":"2011","unstructured":"Albanese, A.  et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur. J. Neurol. 18, 5\u201318 (2011).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201686_CR7","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/DCR.0b013e3181e23dfe","volume":"53","author":"WB Perry","year":"2010","unstructured":"Perry, W. B., Dykes, S. L., Buie, W. D. & Rafferty, J. F. Practice parameters for the management of anal fissures (3rd revision). Dis. Colon Rectum 53, 1110\u20131115 (2010).","journal-title":"Dis. Colon Rectum"},{"key":"BFnrneurol201686_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/CPJ.0000000000000243","volume":"6","author":"R Govindarajan","year":"2016","unstructured":"Govindarajan, R., Shepard, K. M., Moschonas, C. & Chen, J. J. Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Payment policy perspectives. Neurol. Clin. Pract. 6, 1\u20136 (2016).","journal-title":"Neurol. Clin. Pract."},{"key":"BFnrneurol201686_CR9","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00415-015-7703-x","volume":"262","author":"A Albanese","year":"2015","unstructured":"Albanese, A.  et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J. Neurol. 262, 2201\u20132213 (2015).","journal-title":"J. Neurol."},{"key":"BFnrneurol201686_CR10","doi-asserted-by":"publisher","unstructured":"Marion, M. H., Humberstone, M., Grunewald, R. & Wimalaratna, S. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin. Pract. Neurol. \n                    http:\/\/dx.doi.org\/10.1136\/practneurol-2015-001335\n                    \n                   (2016).","DOI":"10.1136\/practneurol-2015-001335"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.86.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.86","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.86.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:20:30Z","timestamp":1684470030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2016.86"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,17]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFnrneurol201686"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2016.86","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,17]]},"assertion":[{"value":"17 June 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has received speaker's honoraria from Allergan, Ipsen and Merz.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}